Differentiating ARBs for Hypertension

ARB Selection Based on Clinical Context

• The American College of Cardiology recommends losartan for patients with left ventricular hypertrophy, as it reduces cardiovascular events by 13% and stroke by 25% 3, 4, 5
• The European Society of Cardiology suggests candesartan or valsartan for heart failure with reduced ejection fraction, as they reduce mortality and hospitalization 6, 7, 2
• The American Diabetes Association recommends losartan or irbesartan for diabetic patients with nephropathy, as they have renoprotective effects 7, 9, 2
• The European Heart Journal states that all ARBs are acceptable for patients with diabetes and nephropathy, but losartan and irbesartan have specific trial data 7, 9, 2

Dosing Recommendations

• The American Heart Association recommends initiating ARBs at low doses in elderly patients and titrating gradually due to increased risk of adverse effects 3
• The European Society of Hypertension suggests targeting blood pressure <130/80 mmHg in all patients, and <120/80 mmHg in heart failure patients 6

Safety Profile and Tolerability

• The American College of Cardiology notes that all ARBs have significantly fewer adverse effects than ACE inhibitors, particularly regarding cough 8, 1, 5
• The European Heart Journal states that the incidence of adverse events with ARBs is comparable to placebo in most studies 8